Antibody-Antigen Interaction Analysis by BLI
Understanding antibody-antigen interactions is critical in developing antibody drugs, and CD BioSciences offers advanced biolayer interferometry (BLI) services to provide efficient and accurate antibody-antigen interaction analysis solutions to accelerate the development of antibody drugs.
Background
When developing and designing antibodies for various purposes, such as diagnostics or therapeutics, comprehensive characterization is required to determine affinity, specificity, and mechanism of action. Biolayer interferometry (BLI) is a label-free, real-time optical detection technique widely used to measure antibody-antigen interactions. and calculates important data such as affinity (KD), binding rate (ka), and dissociation rate (kd) between molecules. Tongan BLI enables accurate quantification of biomolecules as well as real-time, label-free analysis of biomolecular kinetics and affinity.
BLI technology can detect various samples such as proteins, nucleic acids, small molecule drugs, antibodies, etc., and has been widely used in life science research fields such as protein structure target analysis, drug development, and immunology.
Figure 1. Characterization of antibody-antigen interactions using biolayer interferometry. (Noy-Porat T, et al., 2021)
Our Services
- Antibody Screening and Characterization
Our services include providing binding kinetic analysis, affinity assessment, and specificity analysis. To screen the best candidate antibodies, we measure the binding and dissociation rates of antibodies to antigens and calculate the binding constant (Kd) to evaluate the affinity and specificity of antibodies.
- Antibody Affinity Optimization
Improving the affinity of antibodies is a key step in optimizing antibodies. We use BLI technology to analyze the binding kinetics of antibody mutants and further screen mutants with higher affinity. In addition, by deeply studying the binding mechanism of antibodies to antigens, our team can guide the design and optimization of antibodies to enhance the affinity of antibodies.
- Antibody Stability Assessment
The stability of antibodies is critical to their effectiveness and safety as drugs. Our platform can provide binding stability testing services, by measuring the stability of antibody-antigen complexes under different conditions, further evaluating the thermal stability and physical stability of antibodies. At the same time, we also perform competitive binding assays to study the binding behavior of antibodies in the presence of different ligands or inhibitors and evaluate their performance in complex biological environments.
- High-throughput Screening
Our service platform supports high-throughput screening, which can process multiple samples at the same time, significantly improving the screening efficiency and data output speed of antibodies. By performing multi-sample parallel analysis with an automated system, we ensure efficient and accurate result output and provide our customers with reliable antibody-antigen interaction data.
Applications
- Antigen-antibody affinity testing
- Antibody subtyping
- Antibody pairing
- Antibody affinity and kinetic assays
Our Strengths
- Comprehensive technology platform. Our platform is equipped with state-of-the-art equipment to ensure the delivery of highly sensitive and accurate analytical results.
- Highly specialized. Our team has rich experience in antibody R&D and can provide professional technical support to our customers.
- Customized service process. We will provide a one-stop service from antibody screening, and characterization to optimization according to customers' different needs.
CD BioSciences has established a professional BLI platform to provide customers with antibody-antigen interaction analysis services. Our specialized biophysical analysis technology will provide you with important technical support in the field of antibody development. If you are interested in our services, please contact us for more details.
Reference
- Noy-Porat T, Alcalay R, Mechaly A, et al. (2021). Characterization of antibody-antigen interactions using biolayer interferometry[J]. STAR protocols. 2(4): 100836.
For research use only, not
intended for any clinical use.
Related Services
